AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01760993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
Study NCT02855684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02855684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02855684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-insulin antihyperglycemic drugs
Description: Pharmaceutical form: capsule/tablet~Route of administration: oral
Study NCT02855684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-insulin antihyperglycemic drugs
Description: Pharmaceutical form: capsule/tablet~Route of administration: oral
Study NCT01907984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT01907984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01907984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT00734344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg. BID
Study NCT04333758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jintronix Virtual Reality Telerehabilitation System
Description: System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training.
Study NCT00723450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamictal
Description: Flexible Dosing
Study NCT00723450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamictal
Description: Flexible Dosing
Study NCT02968472 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: prophylactic 4SCAR19 cells
Description: Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
Study NCT01147341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimzia
Description: prefilled 200mg Cimzia syringe SC q 2 weeks
Study NCT01147341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prefilled saline syringe
Study NCT04000269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix MxN Neuromodulation device
Description: Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
Study NCT03060837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Movement of kidney
Description: Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
Study NCT03060837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single lung ventilation
Description: Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
Study NCT03060837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard ventilation
Description: Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
Study NCT01527565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
Study NCT01937065 — intervention group
Intervention type: OTHER
Intervention: No treatment
Study NCT00845702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine (Dotarem)
Description: Each subject will receive one injection of Dotarem 0.2 ml/kg
Study NCT00845702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time of Flight Magnetic Resonance Angiography
Description: Each subject will undergo a TOF MRA
Study NCT04000269 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
Study NCT01272921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Varying doses to determine the duration of analgesia
Study NCT01983514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8IU intranasal oxytocin
Study NCT01983514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Study NCT01983514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 IU intravenous oxytocin
Study NCT01983514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02280720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting using Optimax™
Study NCT02280720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting using PROMUS Element™ Plus
Study NCT02623452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study NCT02623452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study NCT02190448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: study herbal tea
Description: 3-5 cups, 8oz tea daily for 4 weeks
Study NCT02190448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: herbal placebo tea
Description: 3-5 cups, 8oz each daily for 4 weeks
Study NCT03352375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheally intubation
Description: Interventions used for airway safety and ventilation during surgical procedures
Study NCT04815863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of somatic symptom disorder with SSS-CN
Description: SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
Study NCT04815863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of depressive symptoms disorder with PHQ-9
Description: PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
Study NCT04815863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of anxiety disorder with GAD-7
Description: GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
Study NCT00108381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tailored cognitive behavior therapy
Description: tailored psychological treatment
Study NCT00108381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard psychological treatment
Study NCT00876941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Brief Intervention
Description: Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor.
Study NCT00876941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Intervention
Description: Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings.
Study NCT00876941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: Information and Feedback
Description: Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Administered IV
Study NCT02314117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered IV
Study NCT02894749 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D rotational angiography (3DRA)
Description: 3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
Study NCT01336439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A (Meditoxin®)
Description: In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography.
Study NCT02878330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897
Description: A single IM dose of 50 mg on Day 1 of the study.
Study NCT02878330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
Study NCT04402957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT peptide
Description: LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
Study NCT04402957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution
Study NCT03782350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Dosage 1
Description: Tranexamic Acid Dosage 1
Study NCT03782350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Dosage 2
Description: Tranexamic Acid Dosage 2
Study NCT01142180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAE
Description: The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
Study NCT01142180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No TAE
Description: No TAE procedure will be performed after endoscopic treatment
Study NCT02369536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutraceutical mixture
Description: Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
Study NCT02369536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
Study NCT01600287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IAADS
Description: In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol.
Study NCT01600287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual propofol administration
Description: In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value.
Study NCT02040714 — intervention group
Intervention type: PROCEDURE
Intervention: Osteotomy + Long Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
Study NCT03429998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab
Description: evolocumab 140 mg/biweekly
Study NCT03429998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab and LDL apheresis
Description: evolocumab 140 mg/biweekly LDL-apheresis monthly
Study NCT03429998 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LDL apheresis
Description: LDL apheresis biweekly
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
Study NCT02040714 — intervention group
Intervention type: PROCEDURE
Intervention: Osteotomy + Short Term Non-Weight Bearing
Description: Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a (P)
Description: 180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
Study NCT00980330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: 1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
Study NCT03580798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed graft
Description: 8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
Study NCT03580798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous graft
Description: At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
Study NCT01285830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
Study NCT01285830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
Study NCT02040714 — intervention group
Intervention type: PROCEDURE
Intervention: Nonoperative Observation
Description: Group will not undergo any surgical or invasive procedures during course of treatment.
Study NCT01679951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
Study NCT01679951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (3 mg)
Description: Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
Study NCT01679951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (10 mg)
Description: Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
Study NCT01679951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (30 mg)
Description: Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
Study NCT01679951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
Study NCT01679951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
Study NCT00316836 — intervention group
Intervention type: PROCEDURE
Intervention: mammography